1. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Issue 2 (20th December 2021) Authors: Ding, Yiming; Zhang, Chuanbao; He, Lei; Song, Xinyu; Zheng, Chengjun; Pan, Yuchu; Yu, Shuqing Journal: Bioengineered Issue: Volume 12:Issue 2(2021) Page Start: 10791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model. Issue 1 (5th January 2023) Authors: Chai, Sanbao; Yu, Shuqing; Liu, Fengqi; Liu, Zuoxiang; Yang, Qingqing; Sun, Feng Editors: Ni, Jing Journal: Chinese medical journal Issue: Volume 136:Issue 1(2023) Page Start: 102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. Issue 1 (20th September 2019) Authors: Chai, Sanbao; Yu, Shuqing; Yang, Zhirong; Wu, Shanshan; Gao, Le; Wang, Haining; Zhang, Yuan; Zhan, Siyan; Ji, Linong; Sun, Feng Journal: BMJ open diabetes research and care Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗